Abstract | BACKGROUND: CASE REPORT: A 21-year-old male self-ingested 750 mg-tramadol, 200 mg-sotalol, 400 mg-propranolol and 6 mg-lorazepam. He was a kidney transplant patient treated with mycophenolate, tacrolimus, prednisone, and paroxetine. He developed transitory cardiovascular failure and prolonged serotonin toxicity requiring sedation, muscle paralysis, and cyproheptadine, with a favorable outcome. METHODS: We measured plasma concentrations of tramadol, M1, M2, and M5 using liquid-chromatography-tandem mass spectrometry, calculated elimination half-lives and metabolic ratios of the compounds, and genotyped cytochromes involved in tramadol metabolism. RESULTS: Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged. M1 metabolic ratio (0.12) was 2-fold reduced, M2 metabolic ratio (197) 1000-fold increased and M5 metabolic ratio (0.12) normal. This metabolic profile in a patient with normal CYP2D6-metabolizer status based on genotyping supports CYP2D6 inhibition by paroxetine and propranolol, two strong mechanism-based inhibitors. Only M2 present in sufficient concentrations up to 48 h could explain the prolonged serotonin toxicity. CONCLUSION:
|
Authors | Guillaume Bianconi, Isabelle Malissin, Laurence Labat, Nihel Khoudour, Pascal Houzé, Nicolas Pallet, Bruno Mégarbane, Xavier Declèves |
Journal | Clinical toxicology (Philadelphia, Pa.)
(Clin Toxicol (Phila))
Vol. 60
Issue 3
Pg. 382-385
(Mar 2022)
ISSN: 1556-9519 [Electronic] England |
PMID | 34287102
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Serotonin
- Tramadol
- Cytochrome P-450 CYP2D6
|
Topics |
- Adult
- Cytochrome P-450 CYP2D6
(genetics, metabolism)
- Humans
- Male
- Serotonin
(toxicity)
- Tramadol
(poisoning)
- Young Adult
|